Edition:
United States

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

7.85USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$7.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,353
52-wk High
$9.10
52-wk Low
$2.15

Chart for

About

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $120.46
Shares Outstanding(Mil.): 14.17
Dividend: --
Yield (%): --

Financials

  XENE.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -1.50 -- --
ROI: -59.10 -5.33 13.09
ROE: -84.26 -6.88 15.10

BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference

* XENON PRESENTS POSITIVE XEN1101 TMS PHARMACODYNAMIC PHASE 1 DATA AT 14TH EILAT CONFERENCE

May 15 2018

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 08 2018

BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING

May 08 2018

BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results

* XENON PHARMACEUTICALS TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 07 2018

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Feb 20 2018

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

Jan 08 2018

Earnings vs. Estimates